The US FDA has approved the first telemonitoring protocol for a clinical trial involving a hypertensive drug for 180 patients who also suffer from multiple sclerosis.  Participants will wear a vital signs sensor that collects biometric data and records medication adherence.  The cost of the year long monitoring is estimated at $1.5m, compared to $5m for conventional reporting.  MORE